Skip to main content

Table 1 Patient characteristics

From: Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab

  Number of patients (%)
Age
  ≤ 65 years 9 (41)
  > 65 years 13 (59)
Sex
 Female 6 (27)
 Male 16 (73)
Eastern Co-operative Oncology Group (ECOG) performance status (PS)
 0 11 (50)
 1 9 (41)
 2 2 (9)
UICC stage
 III 22 (100)
T descriptor
 1–2 6 (27)
 3–4 16 (73)
N descriptor
 0–1 5 (23)
 2–3 17 (77)
Histology
 Squamous cell carcinoma (SCC) 10 (45)
 Adenocarcinoma (AC) 10 (45)
 Large cell neuroendocrine cancer (LCNEC) 2 (9)
Tobacco consumption (PY)
 0 2 (9)
 20–40 8 (36)
  > 40 12 (55)
Durvalumab completion rate
 50% (12 or more cycles) 15 (68)
 100% (24 cycles) 8 (36)
Reason for treatment discontinuation
 Progress 8 (50)
 Toxicity 5 (31)
 Compliance 1 (6)
Induction chemotherapy 7 (32)
Concurrent chemotherapy 21 (95)
PTV > 700 ccm 9 (41)
PTV < 700 ccm 13 (59)